Global Corporates at BioTrinity in 2011
A significant cohort of Global Corporates were represented at BioTrinity 2011, including senior licensing and corporate venture arms from the top 10 global pharma, principally attending to look for in-licensing, M&A and investment opportunities.
- Abbott Biotech Ventures (Director, Venture Investments)
- Allergan (VP Business Development, EAME)
- AstraZeneca (VP Strategic Partnering and Business Development)
- Baxter (Pharma Partner Executive)
- Boehringer Ingelheim GmbH, Germany (Investment Manager)
- Eli Lilly (Executive Director, Global External R&D, Europe and MENA)
- GSK-CEEDD (Director, Scientific Opportunities)
- Inventages Venture Capital (Chairman)
- Ironwood Pharmaceuticals (Executive Director Business Development)
- J&J Dev Corp, US (Vice President, Venture Investments)
- Lundbeckfond, Denmark (Senior Investment Manager)
- Merck Serono Ventures, Switzerland (Head)
- Merck Sharpe & Dohme Limited (Senior Director and Head, Licensing and External Research Europe)
- MP Healthcare Venture Management, US (Senior Manager)
- Novartis Oncology (Director, Global Alliance Management, Oncology Business Development and Licensing)
- Novo A/S, Denmark (Senior Partner)
- Pfizer, Inc. (Head, Cardiovascular, Metabolic and Entero/Endocrine Diseases, External Research and Development Innovation)
- Pfizer, Inc. (Senior Director, R&D Strategic Planning)
- Roche Pharma Partnering (Strategic Business Partner, Communication)
- sanofi-aventis (sanofi-aventis R&D, Partnering & Innovation)
- Shanghai Fosun Pharma, China (Investment Director, International)
- Shire (SVP, Strategic Investment Group)
- Shire (Director, Business Development)
- Smith and Nephew (Science Manager)
- SR One (Vice President, Partner)
- Takeda Pharmaceuticals Europe (Senior Director, Global Business Development)
- Takeda Ventures, Inc., US (President & CEO)
- Teva (Senior Partnering Director, Teva Innovative Ventures)
Global Pharma Companies Attending BioTrinity in 2010
Bringing global pharma together with R&D companies and investors is the key to BioTrinity's success. The following global pharma companies have already confirmed attendance: Novartis, Merck, Pfizer, GSK, BMS, Shire, Takeda, Boehringer, Genzyme, Teva, OSI, UCB, Daiichi Sankyo and Ranbaxy:
- Alliance Pharma (Business Development Director)
- AstraZeneca (Director, Science and Technology Alliances)
- BMS (Executive Director, Head of Europe, Global Search, Strategic Transactions Group)
- Boehringer Ingelheim (Head of Global Licensing for Respiratory)
- Daiichi Sankyo Europe Gmbh (Germany) - Director Business Development & Licensing Europe
- Genzyme Therapeutics UK and Ireland
- GSK (Director, Commercial Alliances & Transactions and VP Pipeline Progression and Director of Scientific Opportunities and Research Director CEEDD)
- Merck (Directors, Licensing & External Research)
- Novaratis Pharmaceuticals Corporation (US) -VP & Head, Oncology BD&L
- OSI Pharmaceuticals (EVP Corporate Development & Strategic Planning)
- Pfizer (Senior Director, Worldwide Licensing and Business Development Group)
- Ranbaxy (India) - (Director, Licensing)
- Shire (SVP Business Development)
- Takeda Global R&D Centre (Europe) - Senior Director, Global Licensing and Business Development
- Teva (Senior Partnering Director)
- UCB (VP UCB NewMedicines Business Development & Partnering)
Sixty-five percent of the world's top 20 global pharma were respresented at senior level at BioTrinity 2009:
AstraZeneca (Alliance Manager)
Bristol Myers-Squibb (Director, External Science Technology & Licensing)
Eli Lilly (Associate Directors, Global External Development & Research)
Genzyme (US) (VP Business Development, Oncology and MS)
GSK (Director, Transactions, Worldwide Business Development)
Merck (Director, Scientific & Academic Liaison Licensing and External Research)
Novartis - Switzerland (Head of Strategic Alliances)
(OSI) Pharmaceuticals (President of Prosidion)
Pfizer (Senior Director, Worldwide Licensing and Business Development Group)
Roche (Switzerland, Global Head of Licensing)
Shire Pharma (SVP and Associate Director, Business Development)
Takeda Pharmaceuticals (Senior Director, Global Licensing & Business Development)
Teva Pharmaceutical Industries (Senior Partnering Director)
